anzup therap study (lu-177 psma-617 vs. cabazitaxel): overall survival after 3 years follow-up
Published 2 years ago • 2.7K plays • Length 10:28Download video MP4
Download video MP3
Similar videos
-
11:23
therap study: lu-psma vs. cabazitaxel #asco20 #anzup
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
4:08
lu-177 psma-617 versus vs cabazitaxel: therap trial @ snmmi 2021
-
0:16
lutetium-177 psma therapy
-
6:40
updated overall survival outcomes in enzamet (anzup 1304)
-
0:57
real-world outcomes of 177lu-psma-617 in mcrpc
-
3:01
preliminary findings in mcrpc for fractionated dose 177lu-psma-617
-
6:43
does sugar feed prostate cancer? does fatty/adipose tissue attract cancer? | mark moyad, md, mph
-
5:58
need to know: experience with lutetium (pluvicto) for prostate cancer theranostics
-
8:49
limitations of lutetium-177-psma & addressing treatment challenges
-
2:56
therap: lupsma versus cabazitaxel for prostate cancer
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
4:48
vision: lu-177-psma-617 in mcrpc
-
4:46
lutetium-177–psma-617: appropriate and potential off-label utility
-
6:59
first results of therap trial
-
3:34
abacus trial: preoperative atezolizumab in urothelial carcinoma
-
10:47
therap trial
-
2:24
eclipse - a randomized phase 3 trial for 177-lu-psma-i&t in patients with mcrpc
-
11:49
lutetium-177 (pluvicto) vs. psma-actinium | #markscholzmd #alexscholz #pcri
-
5:37
177lu-psma-617 for the early treatment of prostate cancer